Overview
Semaglutide is classified as a glp-1 agonist peptide. Fat loss, appetite control, cardiovascular benefits.
GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection.
Also known as: Ozempic, Wegovy, Rybelsus
Category
GLP-1 Agonist
Half-Life
168h
Route
SubQ
FDA Status
Approved
How Does Semaglutide Work?
GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection.
At the molecular level, Semaglutide operates through pathways characteristic of the GLP-1 Agonist class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]STEP 1: Semaglutide 2.4 mg for weight management
Wilding et al. (NEJM): Landmark STEP 1 trial semaglutide 2.4mg achieved 14.9% mean weight loss vs 2.4% placebo at 68 weeks in 1,961 adults with obesity.
Evidence: very strong[2]SELECT trial: semaglutide reduces cardiovascular events by 20%
Lincoff et al. (NEJM): SELECT trial shows semaglutide 2.4mg reduces major adverse cardiovascular events by 20% in overweight/obese adults with established CVD.
Evidence: very strong[3]STEP program overview: pooled Phase 3 weight loss data
Comprehensive analysis across STEP trials showing 14.9-17.4% weight loss, improved cardiometabolic risk factors, blood pressure, and quality of life with semaglutide 2.4mg.
Evidence: very strong[4]Oral semaglutide (Rybelsus) in type 2 diabetes PIONEER program
Aroda et al. (JAMA): PIONEER trials demonstrate oral semaglutide achieves significant HbA1c and weight reductions, representing the first oral GLP-1RA for type 2 diabetes.
Evidence: very strong[5]Semaglutide cognitive and neurological effects emerging research
Emerging evidence suggests semaglutide may have neuroprotective properties, with trials underway for Alzheimer's disease and other neurodegenerative conditions.
Evidence: emergingSafety Profile
FDA-approved for diabetes (Ozempic) and obesity (Wegovy). Well-studied long-term. GI side effects possible. Prescription required.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~44% of users | moderate |
| Diarrhea | ~30% of users | mild |
| Vomiting | ~24% of users | moderate |
| Constipation | ~24% of users | mild |
| Pancreatitis | Rare (<1%) | rare |
Sourcing Semaglutide for Research
If you're looking to source Semaglutide for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
Semaglutide — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.